Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ adverse effects
Biopsy
CTLA-4 Antigen
/ antagonists & inhibitors
Colitis
/ diagnosis
Colon
/ immunology
Diagnosis, Differential
Female
Gastritis
/ diagnosis
Gastrointestinal Diseases
/ diagnosis
Humans
Inflammation
/ diagnosis
Male
Middle Aged
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Retrospective Studies
Stomach
/ immunology
Upper Gastrointestinal Tract
/ immunology
CTLA-4
PD-1
checkpoint proteins
gastrointestinal
immune-mediated adverse events
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
27
05
2019
accepted:
29
07
2019
pubmed:
31
7
2019
medline:
1
7
2020
entrez:
31
7
2019
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) improve survival across a range of malignancies but are also associated with a spectrum of gastrointestinal (GI) immune-related adverse events (GI-irAEs). The aims of this study were to explore the diagnostic value of gastric and duodenal biopsies and to address considerations in the differential diagnosis. We identified 39 patients who were treated with ICIs and had a subsequent upper GI biopsy. We recorded clinical data and endoscopic findings, and reviewed their gastric, duodenal and colonic biopsies. Twenty-one (54%) patients were treated with an anti-programmed cell death protein 1 (PD-1)/anti-programmed cell death ligand 1 antibody alone, and 17 (44%) patients were treated with a combination of anti-cytotoxic T-lymphocyte-associated protein-4 and anti-PD-1 antibodies. Thirty-two (82%) patients presented with diarrhoea. Gastric alterations included periglandular inflammation and granulomas, and duodenal changes included villous blunting, intraepithelial lymphocytosis, granulomas, and neutrophilic activity. We recognised four patterns of colonic injury: (i) acute self-limiting colitis; (ii) lymphocytic colitis; (iii) collagenous colitis; and (iv) apoptosis-only. Twenty-nine (74%) and 10 (26%) patients were diagnosed clinically as positive and negative for GI-irAEs, respectively. Gastric periglandular inflammation (P = 0.004) and an increased number of colonic lamina propria mononuclear cells (P = 0.04) correlated with the clinical diagnosis of a GI-irAE. Histological alterations associated with ICI injury were more often identified in upper GI biopsies (71%) than in colonic biopsies (65%). The morphological spectrum of ICI-related GI disease is broad, and mimics a range of infectious and inflammatory diseases. Gastric periglandular inflammation represents one of the more characteristic histological features of GI-irAEs. The study underscores the importance of a comprehensive review of upper and lower GI biopsies for the diagnosis of GI-irAEs.
Identifiants
pubmed: 31361907
doi: 10.1111/his.13963
pmc: PMC8386137
mid: NIHMS1724474
doi:
Substances chimiques
Antibodies, Monoclonal
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-243Subventions
Organisme : NIDDK NIH HHS
ID : K08 DK114563
Pays : United States
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
J Clin Oncol. 2015 Oct 1;33(28):3193-8
pubmed: 26282644
Aliment Pharmacol Ther. 2015 Aug;42(4):406-17
pubmed: 26079306
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Ann Oncol. 2017 Feb 1;28(2):368-376
pubmed: 27687304
Cancer. 2018 Sep 15;124(18):3706-3714
pubmed: 29975414
Oncoimmunology. 2017 Jul 5;6(10):e1344805
pubmed: 29123955
Front Immunol. 2017 Nov 15;8:1547
pubmed: 29230210
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Melanoma Res. 2018 Dec;28(6):645-647
pubmed: 30256271
Histopathology. 2017 Mar;70(4):558-567
pubmed: 28000302
Am J Surg Pathol. 2014 Oct;38(10):1319-29
pubmed: 25188868
Am J Surg Pathol. 1996 Oct;20(10):1161-81
pubmed: 8827022
Am J Surg Pathol. 2008 Aug;32(8):1130-7
pubmed: 18545145
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Trends Immunol. 2019 Jun;40(6):511-523
pubmed: 31053497
Am J Surg Pathol. 2015 Dec;39(12):1653-60
pubmed: 26426383
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Ann Oncol. 2017 Nov 1;28(11):2860-2865
pubmed: 29045560
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Oncologist. 2018 Sep;23(9):991-997
pubmed: 29853659
Gut. 2018 Nov;67(11):2056-2067
pubmed: 30131322
Melanoma Res. 2016 Jun;26(3):308-11
pubmed: 26990271
Oncologist. 2015 Jul;20(7):812-22
pubmed: 26069281
Hum Pathol. 2009 Jul;40(7):909-17
pubmed: 19524102